English

The Taiwan Stock Exchange Corporation held its 755th Listing Review Committee meeting on March 4, 2022 and approved the application of Polaris Group for primary listing. Read more..

Multinational biotech company Polaris signed an industry sponsored research agreement with UC Irvine’s (UCI) Vaccine Research and Development Center to fund “Fluvid,” a universal messenger RNA (mRNA) influenza and coronavirus vaccine. Polaris will use the vaccine technology to increase development of vaccines and cancer treatments with the goal being the first company to make mRNA technology more accessible in …

Polaris Pharmaceuticals steps into mRNA technology and actively integrates macromolecular pharmaceutical technology Read More »

Polaris Group Polaris Pharmaceuticals – KY (6550TW) rush to the stock exchange to apply for the first listing of shares before the end of 2021! Polaris Pharmaceutical-KY submitted an application for listing on the 27th. It is the second foreign company to apply for the first listing in this (2021) year. . The person in …

Polaris Pharmaceuticals applies for the first listing Read More »

Polaris Group has entered into an agreement with the University of California,Irvine(UCI) to develop a universal influenza and coronavirus vaccine.

Polaris Pharmaceuticals (6550TW) announced today that Dr. Philip Felgner of the University of California, Irvine will officially join the Polaris Technical Advisory Board on September 1. CEO Mr. Chen said that Dr. Felgner will bring his decades of experience in mRNA technology and related contacts to Polaris, which will bring substantial and timely benefits to …

Polaris Announces Dr. Philip Felgner Joins the Team Read More »

Polaris Pharmaceuticals announced today that Dr. Yali Tsai has joined Polaris as Vice President of Gene Delivery Technology. With over 25 years of hands-on experience in drug delivery technology and manufacturing, Dr. Tsai has developed a wide range of drugs, including injectable drugs, ophthalmic drugs and skin drugs, and has extensive experience in the development of specialty dosage forms such as microlipids, nanoemulsions and suspension particles.

Polaris Pharmaceuticals (6550TW) held its 2021 Annual Meeting of Shareholders on (8/23) and announced that it will initiate the world’s first Phase III clinical trial of a single drug for liver cancer screened by genetic biomarkers. The Polaris research and development team analyzed the genes of patients who had participated in liver cancer clinical trials …

Polaris Announces Launch of World’s First Phase III Clinical Trial of Genetic Markers for Liver Cancer Read More »

After consultation with FDA, Polaris will follow Data and Safety Monitoring Board’s (DSMB) recommendation to stop Phase III study in lung mesothelioma due to current success and difficulty in continued enrollment